Werewolf Therapeutics, Inc.
HOWL Healthcare Biotechnology
Werewolf Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.9 million, down 90.5% from fiscal 2023. In the quarter to June 2026, revenue grew 256.1%, EPS grew 120.0% and free cash flow grew 146.5%, each against the same quarter a year earlier.
Follow HOWL
Werewolf Therapeutics, Inc. (HOWL) Piotroski F-score
Werewolf Therapeutics, Inc.'s Piotroski F-score for fiscal 2024 is 3 out of 9: 3 of nine tests of profitability, leverage and efficiency passed.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2024 | 3 | — |
How fiscal 2024’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (46.74%) | (22.30%) | Fail | 0 |
| Positive operating cash flow | (56.19m) | (32.61m) | Fail | 0 |
| Rising return on assets | (46.74%) | (22.30%) | Fail | 0 |
| Cash flow above net income | 14.33m | 4.76m | Pass | 1 |
| Falling long-term leverage | 0.17 | 0.19 | Pass | 1 |
| Rising current ratio | 7.45 | 7.14 | Pass | 1 |
| No new shares issued | 43,332,000 | 35,647,000 | Fail | 0 |
| Rising gross margin | 100.00% | 100.00% | Fail | 0 |
| Rising asset turnover | 0.01 | 0.12 | Fail | 0 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 3 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| ELTX Elicio Therapeutics, Inc. compare | 6 |
| HYPD Hyperion DeFi, Inc. compare | 5 |
| IBIO iBio, Inc. compare | 4 |
| ACET Adicet Bio, Inc. compare | 4 |
| HOWL Werewolf Therapeutics, Inc. | 3 |
| CRBU Caribou Biosciences, Inc. compare | 3 |
| MREO Mereo BioPharma Group plc - Sponsored ADR compare | — |
| LONA LeonaBio, Inc. compare | — |
| KLRS Kalaris Therapeutics Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover